Ajax, aiming for a better JAK drug, raises $95M to begin first tests

Medicines called JAK inhibitors are well known in the pharmaceutical industry. Several are approved to treat inflammatory disease conditions or cancer, and regularly bring in billions of dollars in yearly revenue for drugmakers like AbbVie and Pfizer.